Nigeria's new health minister supports LuViva cervical-cancer scan
Before assuming his current position, Adewole presented the results of his study last year at the Society of Gynecology and Obstetrics of Nigeria. The study showed LuViva detected 100 percent of serious pre-cancerous growths and screened out up to 40 percent of false-positive results.
“These results are encouraging and demonstrate the value of LuViva as a means to detect cervical disease, even in the absence of a positive human papillomavirus result, while also providing a means to reduce unnecessary additional testing," Adewole said. "In addition to the accuracy displayed in the study, LuViva is painless and results are immediate -- important attributes for the patient and health care provider, particularly in rural communities.”
Gene Cartwright, CEO and president of Guided Therapeutics, which manufactures LuViva, congratulated Adewole on his appointment.
“We look forward to working with Minister Adewole and the Ministry to advance the state of women’s health in Nigeria and all of Africa,” Cartwright said.
Adewole has done extensive research in the areas of human papillomavirus, HIV and gynecologic oncology. His study on LuViva involved 100 patients and was conducted at University Teaching Hospital in Ibadan, Nigeria.
More information about LuViva is available at www.guidedinc.com.